Details : Proceeds will be used to advance phase 1 trials of two pipeline candidates, EI-1071 and EI-001 and take three immuno-oncology assets towards IND applications .
Product Name : EI-1071
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 23, 2021
Details : Grant Program will support a U.S. FDA-approved first-in-human phase 1 clinical trial of its lead drug candidate, EI1071, an orally available, highly potent Colony-Stimulating Factor 1 Receptor (CSF1R) inhibitor.
Product Name : EI-1071
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 26, 2020
Lead Product(s) : Pregabalin,Naproxen
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NDA Application of XG005 will Follows a Regulatory Pathway Bosed on FDA’s Feedback
Details : XG005 is a drug conjugate of naproxen and pregabalin which is being investigated for the management of acute pain.
Product Name : XG005
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 22, 2020
Lead Product(s) : Pregabalin,Naproxen
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable